[go: up one dir, main page]

FI960556A0 - Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä - Google Patents

Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä

Info

Publication number
FI960556A0
FI960556A0 FI960556A FI960556A FI960556A0 FI 960556 A0 FI960556 A0 FI 960556A0 FI 960556 A FI960556 A FI 960556A FI 960556 A FI960556 A FI 960556A FI 960556 A0 FI960556 A0 FI 960556A0
Authority
FI
Finland
Prior art keywords
delivery system
slow flow
active drugs
flow delivery
transdermal slow
Prior art date
Application number
FI960556A
Other languages
English (en)
Swedish (sv)
Other versions
FI960556A (fi
Inventor
Eric J Roos
Chia-Ming Chiang
Tsung-Min Hsu
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22300358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI960556(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Publication of FI960556A0 publication Critical patent/FI960556A0/fi
Publication of FI960556A publication Critical patent/FI960556A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI960556A 1993-08-09 1996-02-07 Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä FI960556A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/104,414 US5554381A (en) 1993-08-09 1993-08-09 Low flux matrix system for delivering potent drugs transdermally
PCT/US1994/008883 WO1995004554A1 (en) 1993-08-09 1994-08-05 Low flux transdermal potent drug delivery system

Publications (2)

Publication Number Publication Date
FI960556A0 true FI960556A0 (fi) 1996-02-07
FI960556A FI960556A (fi) 1996-03-11

Family

ID=22300358

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960556A FI960556A (fi) 1993-08-09 1996-02-07 Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä

Country Status (13)

Country Link
US (1) US5554381A (fi)
EP (1) EP0716615B2 (fi)
JP (1) JPH09505554A (fi)
AT (1) ATE309004T1 (fi)
AU (1) AU679557B2 (fi)
CA (1) CA2169164A1 (fi)
DE (1) DE69434537T3 (fi)
DK (1) DK0716615T4 (fi)
ES (1) ES2249763T5 (fi)
FI (1) FI960556A (fi)
NO (1) NO960487D0 (fi)
NZ (1) NZ271797A (fi)
WO (1) WO1995004554A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
WO1997040792A1 (en) * 1996-04-30 1997-11-06 Theratech, Inc. Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19830651A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Steroidhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
ES2270746T3 (es) * 2001-03-16 2007-12-01 Alza Corporation Parche transdermico para administrar fentanilo.
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
AU2003254834B2 (en) 2002-08-09 2009-02-19 Fuso Pharmaceutical Industries, Ltd. Female hormone-containing patch
EP1561814B1 (en) 2002-10-22 2010-12-22 Eisai R&D Management Co., Ltd. Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
SI1426049T1 (en) * 2002-12-02 2005-08-31 Sanol Arznei Schwarz Gmbh Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US8431152B2 (en) * 2005-02-28 2013-04-30 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable preparation
WO2006135785A2 (en) * 2005-06-10 2006-12-21 Medical College Of Georgia Research Institute Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8734413B2 (en) 2007-08-03 2014-05-27 Kimberly-Clark Worldwide, Inc. Packaged body adhering absorbent article
US7947027B2 (en) 2007-12-28 2011-05-24 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US8672911B2 (en) 2007-08-03 2014-03-18 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US20090258061A1 (en) * 2007-10-15 2009-10-15 Johnson & Johnson Once-a-day replacement transdermal administration of fentanyl
WO2009110351A1 (ja) 2008-03-03 2009-09-11 久光製薬株式会社 経皮吸収製剤
US11147722B2 (en) * 2008-11-10 2021-10-19 Kimberly-Clark Worldwide, Inc. Absorbent article with a multifunctional acrylate skin-adhesive composition
US10022468B2 (en) 2009-02-02 2018-07-17 Kimberly-Clark Worldwide, Inc. Absorbent articles containing a multifunctional gel
WO2011014775A1 (en) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (en) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Compositions and Methods for Treating Herpes Simplex Virus
KR20140088199A (ko) * 2011-11-04 2014-07-09 애자일 쎄라퓨틱스, 인크. 경피 전달 조성물 및 방법
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2015027146A1 (en) 2013-08-22 2015-02-26 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
WO2015031765A2 (en) 2013-08-29 2015-03-05 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
BR112018001441A2 (pt) 2015-07-28 2018-09-11 Vyome Biosciences Pvt Ltd antibacterianos terapêuticos e profiláticos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
AU644815B2 (en) * 1989-09-08 1993-12-23 Ortho-Mcneil Pharmaceutical, Inc. Solid matrix system for transdermal drug delivery
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.

Also Published As

Publication number Publication date
EP0716615B2 (en) 2009-10-21
DE69434537D1 (de) 2005-12-15
DK0716615T3 (da) 2006-02-20
ES2249763T3 (es) 2006-04-01
NO960487L (no) 1996-02-06
DE69434537T3 (de) 2010-04-15
FI960556A (fi) 1996-03-11
ES2249763T5 (es) 2010-02-01
US5554381A (en) 1996-09-10
NO960487D0 (no) 1996-02-06
JPH09505554A (ja) 1997-06-03
WO1995004554A1 (en) 1995-02-16
CA2169164A1 (en) 1995-02-16
EP0716615A1 (en) 1996-06-19
EP0716615B1 (en) 2005-11-09
NZ271797A (en) 1997-12-19
AU679557B2 (en) 1997-07-03
DK0716615T4 (da) 2009-12-14
AU7556294A (en) 1995-02-28
ATE309004T1 (de) 2005-11-15
EP0716615A4 (en) 1997-06-11
DE69434537T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
FI960556A0 (fi) Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä
EP0033615B1 (en) Therapeutic system for administering drugs to the skin
US5314694A (en) Transdermal formulations, methods and devices
EP0279977A3 (en) Transdermal administration of progesterone, estradiol esters and mixtures thereof
NO20074292L (no) Anvendelse av buprenorfin i polymermatriks og leveringssystemer
EP0737477A4 (en) TRANSDERMAL PHARMACEUTICAL PREPARATION
WO1992007589A1 (en) Transdermal contraceptive formulations, methods and devices
CA2153572A1 (en) Transdermal therapeutic system with galanthamine as active ingredient
KR900005969A (ko) 게스토덴을 함유하는 경피 투여용 제제
CA2027053A1 (en) Estrogen-Containing Active Substance Plaster
WO2001052823A3 (en) Compositions to effect the release profile in the transdermal administration of drugs
NO852966L (no) Utleveringsanordning for foerste ordensutlevering av en aktiv bestanddel i en opploesningsvaeske, og fremgangsmaate for fremstilling av denne.
HUT74455A (en) Pharmaceutical composition containing estradiol penetration intensifier agent for transdermal administration
PL330212A1 (en) Preparation administered by transcutaneous absorption
GR3018303T3 (en) Transdermal estradiol delivery system.
DK0800386T3 (da) Transdermalt system til samtidig indgivelse af flere aktive stoffer
RU97112182A (ru) Трансдермальная система для одновременной дачи нескольких активных начал
ATE228374T1 (de) Arzneiverabreichungssystem
PL307786A1 (en) Plaster for percutaneous administration of systemically acting steroid hormones
WO1997020582A3 (en) Transdermal patch for comparative evaluations
ATE295157T1 (de) Mittel zur transdermalen verabreichung von arzneistoffen
TW273516B (en) Adhesive matrix-type transdermal therapeutic set for motion sickness

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: CYGNUS, INC.

FD Application lapsed